Top Tweets for #lbcl
Updates from #EHA26: Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory #LBCL. Learn more: https://t.co/itmRYRvJWv
#medtwitter #onctwitter
A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
Missed it the first time? Our EVP of R&D and CMO, Dr. Zachary Roberts, sat down with @JohnCendpts for the @endpts R&D 15 to talk about the ALPHA3 trial and the potential of #allogeneic #CAR T to transform care for patients with #LBCL. $ALLO
Catch the Full Session on Demand: https://t.co/MAnKvn6xD5
Aux termes de l'accord #Servier, #Cellectis 🧬 est éligible à 340 millions de $ en fonction des étapes de développement & de vente, ainsi qu'à des redevances à 2 chiffres sur les ventes de produits #CD19 sous licence, y compris le #Cema_Cel développé dans le cadre du projet #LBCL
🧬#Cellectis 🇫🇷 publie ses résultats financiers pour le T1 26
Phase 2 pivotale avec le lasme-cel dans la #LAL-B R/R (essai BALLI-01)
Phase 1 avec l'éti-cel dans le #LNH R/R (essai NATHALI-01)
https://t.co/1DTkXaluDe
A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
Hoy, en #GELTAMO2026, tenemos el privilegio de contar, en la sesión educacional, con la Dra. María Gomes da Silva:
“Large B‑Cell Lymphoma: Evolving first‑line strategies and sequencing in the era of novel immunotherapies”.
#LBCL #Hematología #Lymphoma
Patients with #LBCL had a sustained increased risk of developing nonischemic HF after chemotherapy. After HF, LBCL history was associated with a higher all-cause but not cardiovascular mortality than comparators. Read in Blood Advances: https://t.co/8rAsQcEZcy
1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an “off-the-shelf” #CART product to intervene early and potentially improve cure rates. $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
Allogene's EVP, R&D and CMO, Dr. Zachary Roberts, recently joined @JohnCendpts for @endpts' R&D 15 to discuss the ALPHA3 trial and how #allogeneic CAR T could potentially reshape treatment for patients with #LBCL. #celltherapy $ALLO
Watch Here: https://t.co/GNTiHpkLtv
Tune in to the @endpts R&D 15 to hear from our EVP, R&D and Chief Medical Officer, Zachary Roberts, MD, PhD in conversation with @JohnCendpts about our ALPHA3 trial, investigating cema-cel as part of 1L treatment for patients with LBCL/DLBCL who are likely to relapse. #allogeneic #celltherapy $ALLO
Register to Watch: https://t.co/s4QuINHgEe
Thank you @BioWorld for highlighting our ALPHA3 interim futility analysis. The findings suggest our #allogeneic #CART candidate may play an important role in eliminating #MRD post-1L treatment for patients with #LBCL. $ALLO
MRD word heard loud, clear in @AllogeneTx LBCL cema-cel phase II https://t.co/iWYHwXt6dq #biopharma #lymphoma
🧬#Allogene 🇺🇸 étend son essai pivotal de phase 2 #ALPHA3 à l'échelle mondiale.
En ajoutant la #CoréeDuSud 🇰🇷 et l'#Australie 🇦🇺 pour atteindre plus de 80 sites dans le monde. 🌍
L'élan se renforce pour #Cema_cel 💉 en 1L #LBCL 🩸, avec le dépistage prévu pour débuter au T2 26.
Big step forward. Allogene is taking its pivotal Phase 2 ALPHA3 trial global – adding South Korea and Australia to reach 80+ sites worldwide. 🌍 Momentum is building for cema-cel in 1L LBCL, with screening expected to kick off in Q2 2026.
https://t.co/Hyn0nQa3yM
Receipt of thiotepa-ASCT was the prognostic variable most favorably associated with survival in a landmark 6-month multivariable analysis. Read in Blood: https://t.co/DWRce3YDyl #LBCL
A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO
Learn More About ALPHA3: https://t.co/pYNVYhm6tO
We recently announced data from an interim futility analysis of the ALPHA3 trial evaluating an #allogeneic #CART in 1L #LBCL consolidation. We believe these early findings have the potential to reshape the field and the future treatment of LBCL. #celltherapy $ALLO
Read Our Announcement: https://t.co/uWBtox6jcE
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.3M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.8M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.8M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.4M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers